LAG3 and small cell lung carcinoma: Furthermore, some trials are ongoing to evaluate anti–PD–(L)1 combined with novel drugs (e.g., LAG–3 blockades and T cell immunoglobulin and mucin domain 3 blockades) for ES–SCLC (94).